Shares of Affirmed Therapeutics BV (NASDAQ:AFMD) saw unusually-high trading volume on Friday . Approximately 174,866 shares were traded during trading, an increase of 62% from the previous session’s volume of 107,795 shares.The stock last traded at $2.77 and had previously closed at $2.95.

AFMD has been the topic of a number of recent analyst reports. Jefferies Group cut their price target on Affirmed Therapeutics BV from $5.00 to $4.00 and set a “hold” rating on the stock in a report on Thursday, May 19th. Leerink Swann cut Affirmed Therapeutics BV from an “outperform” rating to a “market perform” rating in a report on Thursday, May 19th. Finally, Wells Fargo & Co. reaffirmed a “buy” rating on shares of Affirmed Therapeutics BV in a report on Wednesday, May 18th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $9.46.

The company has a 50 day moving average of $2.82 and a 200 day moving average of $3.45. The stock’s market cap is $96.46 million.

Affirmed Therapeutics BV (NASDAQ:AFMD) last announced its quarterly earnings data on Wednesday, August 10th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.22) by $0.05. The firm had revenue of $2.07 million for the quarter, compared to analyst estimates of $2.10 million. During the same period in the prior year, the company earned ($0.19) earnings per share. The business’s revenue was down 6.4% compared to the same quarter last year. Equities analysts expect that Affirmed Therapeutics BV will post ($1.10) EPS for the current year.

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.